June 13, 2025

RSV Vaccine Approved for Younger Adults

The FDA has approved Moderna’s mRESVIA vaccine for adults aged 18 to 59 who are at increased risk for RSV, expanding its indication beyond older adults.

Conexiant

June 13, 2025

Obicetrapib May Offer LDL Benefit

In a randomized trial of more than 2,500 patients at high cardiovascular risk, obicetrapib significantly reduced low-density lipoprotein cholesterol levels when added to existing lipid-lowering therapy.

Conexiant

June 13, 2025

Weight Loss Drugs Show Promise for Heart Failure

ACC statement highlights semaglutide and tirzepatide as therapies associated with improved symptoms and functional capacity in patients with heart failure with preserved ejection fraction and obesity.

Conexiant

June 13, 2025

Experts: HHS Sent Congress ‘Junk Science’

A controversial HHS document supporting RFK Jr.'s rollback of COVID vaccine guidance relies on disputed or misrepresented science, prompting outrage from health experts who call it “willful medical disinformation.”

KFF Health News

June 13, 2025

Endoscopic Sinus Surgery Speeds Recovery

A retrospective study comparing endoscopic and traditional open sinus surgery for chronic rhinosinusitis with nasal polyps found shorter operative times, fewer complications, and improved outcomes associated with the endoscopic technique.

Conexiant

June 13, 2025

JAK Inhibitors Show No Increased Cancer Risk

New real-world data show no significant rise in overall cancer incidence with JAK inhibitors for rheumatoid arthritis patients, though skin cancer monitoring remains important.

Conexiant

June 12, 2025

Medical Oddities: 6 Foot Moves Possibly Worth Prescribing

Strong feet, smarter carbs, test kits, and tea—this roundup’s got range.

Conexiant

June 12, 2025

Gene Variants Linked to CPPD Risk

A large genetic study in U.S. veterans has identified ENPP1 and RNF144B as genes associated with calcium pyrophosphate deposition disease, suggesting potential for targeted treatment approaches.

Conexiant

June 12, 2025

Four Toxins Tested for Glabellar Wrinkle Duration

A new randomized trial using 3D imaging compared four botulinum toxin A formulations in women, revealing differences in onset and durability of glabellar wrinkle reduction over six months.

Conexiant